Z. Tomasevic

1.0k total citations
24 papers, 306 citations indexed

About

Z. Tomasevic is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Z. Tomasevic has authored 24 papers receiving a total of 306 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 7 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Molecular Biology. Recurrent topics in Z. Tomasevic's work include Cancer Treatment and Pharmacology (9 papers), BRCA gene mutations in cancer (4 papers) and Breast Cancer Treatment Studies (4 papers). Z. Tomasevic is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), BRCA gene mutations in cancer (4 papers) and Breast Cancer Treatment Studies (4 papers). Z. Tomasevic collaborates with scholars based in Serbia, United States and Germany. Z. Tomasevic's co-authors include Gϋnter von Minckwitz, Marco Colleoni, Nan Zhang, Vladimir Hanes, Serafín Morales, Patrícia Xavier Santi, Hans‐Christian Kolberg, Ksenija Kanjer, Marko Radulović and Mirjana Branković-Magić and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Z. Tomasevic

22 papers receiving 300 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Z. Tomasevic Serbia 10 150 89 70 47 46 24 306
Junshan Qiu United States 9 124 0.8× 59 0.7× 50 0.7× 54 1.1× 42 0.9× 22 422
Dinesh de Alwis United States 9 276 1.8× 33 0.4× 109 1.6× 28 0.6× 44 1.0× 19 368
Nicola Lucio Liberato Italy 9 85 0.6× 44 0.5× 38 0.5× 82 1.7× 84 1.8× 13 486
Pierre Squifflet Belgium 12 214 1.4× 24 0.3× 97 1.4× 27 0.6× 71 1.5× 20 406
Thomas Gwise United States 10 96 0.6× 20 0.2× 49 0.7× 56 1.2× 56 1.2× 24 316
Helen M. Moore United States 4 57 0.4× 49 0.6× 46 0.7× 38 0.8× 158 3.4× 5 427
Nathalie Varoqueaux France 7 140 0.9× 32 0.4× 52 0.7× 29 0.6× 21 0.5× 19 287
Mitchell S. von Itzstein United States 11 222 1.5× 29 0.3× 60 0.9× 15 0.3× 42 0.9× 32 344
Paul Baverel United States 10 210 1.4× 67 0.8× 90 1.3× 8 0.2× 39 0.8× 28 442
Claire S. Zhu United States 7 108 0.7× 62 0.7× 46 0.7× 27 0.6× 161 3.5× 10 503

Countries citing papers authored by Z. Tomasevic

Since Specialization
Citations

This map shows the geographic impact of Z. Tomasevic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Z. Tomasevic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Z. Tomasevic more than expected).

Fields of papers citing papers by Z. Tomasevic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Z. Tomasevic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Z. Tomasevic. The network helps show where Z. Tomasevic may publish in the future.

Co-authorship network of co-authors of Z. Tomasevic

This figure shows the co-authorship network connecting the top 25 collaborators of Z. Tomasevic. A scholar is included among the top collaborators of Z. Tomasevic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Z. Tomasevic. Z. Tomasevic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tomasevic, Z., et al.. (2021). Long-term trastuzumab treatment in HER2 positive metastatic breast cancer. The Breast. 56. S82–S83.
2.
Krivokuća, Ana, et al.. (2019). Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia. Journal of Human Genetics. 64(4). 281–290. 14 indexed citations
3.
Kovač, Mirjana, et al.. (2019). Breast cancer and recurrent thrombosis — Results from prospective single center study. The Breast Journal. 25(4). 783–785. 1 indexed citations
4.
Minckwitz, Gϋnter von, Marco Colleoni, Hans‐Christian Kolberg, et al.. (2018). Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. The Lancet Oncology. 19(7). 987–998. 84 indexed citations
5.
Popović, Lazar, Z. Tomasevic, Ljiljana Stamatović, et al.. (2018). Serbian consensus of neoadjuvant therapy for breast cancer: NeoPULSE. PubMed. 23(2). 522–532.
6.
Vrdoljak, Eduard, G. Bodoky, Jacek Jassem, et al.. (2018). Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe. The Oncologist. 24(1). e30–e37. 25 indexed citations
7.
Tomasevic, Z., et al.. (2018). Abstract PD3-10: Safety results from a randomized, double-blind, phase 3 study of ABP 980 compared with trastuzumab in patients with breast cancer. Cancer Research. 78(4_Supplement). PD3–10. 2 indexed citations
8.
Jiménez, M. Martín, Bent Ejlertsen, Suzette Delaloge, et al.. (2017). Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial. Annals of Oncology. 28. v43–v44. 3 indexed citations
9.
Krivokuća, Ana, et al.. (2016). Polymorphisms in Cancer Susceptibility Genes XRCC1, RAD51 and TP53 and the Risk of Breast Cancer in Serbian Women. The International Journal of Biological Markers. 31(3). 258–263. 14 indexed citations
10.
11.
Tomasevic, Z., et al.. (2015). Early prognosis of metastasis risk in inflammatory breast cancer by texture analysis of tumour microscopic images. Biomedical Microdevices. 17(5). 92–92. 12 indexed citations
12.
Kanjer, Ksenija, Nebojša T. Milošević, Z. Tomasevic, et al.. (2015). Gray-Level Co-Occurrence Matrix Texture Analysis of Breast Tumor Images in Prognosis of Distant Metastasis Risk. Microscopy and Microanalysis. 21(3). 646–654. 41 indexed citations
13.
Tomasevic, Z., et al.. (2015). Oral administration of antineoplastic agents: the challenges for healthcare professionals.. PubMed. 20(3). 690–8. 12 indexed citations
14.
Krivokuća, Ana, Emina Mališić, Milena Čavić, et al.. (2013). RAD51 135G>C and TP53 Arg72Pro polymorphisms and susceptibility to breast cancer in Serbian women. Familial Cancer. 13(2). 173–180. 14 indexed citations
15.
Kim, Kun, E Hernlund, Zoltán Hernádi, et al.. (2013). Treatment Patterns, Health Care Utilization, and Costs of Ovarian Cancer in Central and Eastern Europe Using a Delphi Panel Based on a Retrospective Chart Review. International Journal of Gynecological Cancer. 23(5). 823–832. 9 indexed citations
16.
Tomasevic, Z., et al.. (2012). Inflammatory Breast Cancer — Does the Confirmation of Dermal Lymphatic Invasion Predict the Worst Outcome?. European Oncology & Haematology. 8(1). 20–20. 1 indexed citations
17.
Tomasevic, Z., et al.. (2012). Clinical and pathological response to induction chemotherapy used as a prognostic factor in inflammatory breast cancer. Single institution experience.. PubMed. 17(1). 21–6. 1 indexed citations
18.
Tomasevic, Z., et al.. (2010). Do we know how many cancer patients have a family history of cancer?. PubMed. 15(1). 127–30. 1 indexed citations
19.
Tomasevic, Z., et al.. (2009). Late relapse in triple negative breast cancer. Journal of Clinical Oncology. 27(15_suppl). e12022–e12022. 2 indexed citations
20.
Tomasevic, Z., et al.. (2003). Negative CEA values in Metastatic Colorectal Carcinoma and the Likelihood of Complete Chemotherapy Response. The International Journal of Biological Markers. 18(1). 28–32. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Junshan Qiu Breakdown of academic impact, for papers by Dinesh de Alwis Breakdown of academic impact, for papers by Nicola Lucio Liberato Breakdown of academic impact, for papers by Pierre Squifflet Breakdown of academic impact, for papers by Thomas Gwise Breakdown of academic impact, for papers by Helen M. Moore Breakdown of academic impact, for papers by Nathalie Varoqueaux Breakdown of academic impact, for papers by Mitchell S. von Itzstein Breakdown of academic impact, for papers by Paul Baverel Breakdown of academic impact, for papers by Claire S. Zhu
Rankless by CCL
2026